Healthcare Professionals

At Zafgen, we’re working to advance safe, effective treatment options that have the potential to significantly improve the health and well-being of patients affected by a range of both rare and more prevalent metabolic disorders where MetAP2 plays a central role. We know that especially in the case of serious and rare metabolic disorders, physicians are waiting for options for their patients, and we are committed to working alongside the community to deliver on the potential of MetAP2 inhibition to positively impact patients’ lives.

Clinical Trials

Zafgen is developing a range of potential first-in-class therapies for type 2 diabetes and other complex metabolic conditions.

ZGN-1061 for the treatment of type 2 diabetes

ZGN-1258 for Prader-Willi syndrome

For more information or questions about trial participation, please contact us at